- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Seattle Cancer Care Alliance | Association Partnerships
Latest from Seattle Cancer Care Alliance
Phase 1/2 Study Examines MB-106 in Various Positive B-cell Malignancies
June 20, 2022
Video
Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16, 2022
Article
In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Investigating CD20 CAR T-Cell Therapy in R/R CLL and Other B-NHL Histologies
May 09, 2022
Video
Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.
Success of Nivolumab Plus Ipilimumab in Advanced RCC Carries Over to Non-Clear Cell Histology
March 11, 2022
Article
Showing similarity to results from CheckMate 214, findings from CheckMate 920 shows that nivolumab plus ipilimumab can safety be administered to patients with non-clear cell renal cell carcinoma.
Newly-Approved Ide-Cel Becomes Available for Treatment at SCCA
May 27, 2021
Article
Idecabtagene vicleucel is now an available treatment option for some patients with relapsed or refractory multiple myeloma who are being treated at Seattle Cancer Care Alliance.